Phase 1 Trial of OCU500 Vaccine Shows Safety and Immunogenicity in Adults
A phase 1 trial is underway to assess the safety and immunogenicity of the OCU500 vaccine in previously vaccinated adults.
Asset / Drug
Drug and asset intelligence for OCU500 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
COVID-19 Vaccine
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.